A platform-driven biotechnology company at the forefront of exosome drug development—committed to translating exosome science into clinically meaningful medicines for CNS, inflammatory, and aging-related diseases.
A glimpse into our research environment, collaboration culture, and commitment to building a global exosome medicines platform.
Our home base in Nanjing, China — where our discovery, engineering, and translational teams work together.
Purpose-built laboratories designed for exosome engineering, RNA loading, and advanced CMC development.
Connecting with partners worldwide to accelerate the development of exosome-based RNA medicines.
P.S.K Biosciences is led by a team with deep experience across exosome biology, RNA therapeutics, clinical development, and global business development.
A structure-guided RNA loading platform (SGRL-Exo™) designed to enable systemic, functional RNA delivery to the CNS and extrahepatic tissues.
Function-defined MSC-derived exosome subpopulations (S1 anti-inflammatory, S2 regenerative) developed into indication-specific therapeutic candidates.
We welcome strategic collaborations with pharmaceutical companies, biotech innovators, academic institutions, clinical centers, and regional development partners.
Explore Partnership Opportunities